Home > About Primary Immunodeficiency (PI) > Treatment

Treating PI With Immunoglobulin (Ig) Therapies1

Ig therapies are one of the treatment options available for treating primary immunodeficiency (PI). However, it is not appropriate for everyone. Talk to your doctor about the different treatment options and what may be best for you.

Why Could Ig Therapy be an Option for You?1,2

When you have PI your body may not be making enough antibodies, or some of the antibodies it's making may not work properly. That’s why you get sick so often. Within your body there are many types of antibodies – Ig (also referred to as IgG or Immunoglobulin), IgM, IgE, IgD and IgA. The Ig antibodies are the ones that help fight off bacteria and viruses that cause infections that can make you sick.

What are Ig Therapies?1

Ig therapies temporarily replace some of the antibodies that your body isn't making on its own or that don't work properly. The goal of this treatment is to help your body fight off bacteria and viruses, and help keep you from getting sick so often.

There are multiple types of Ig therapies that provide options to help meet the needs and preferences of PI patients. Talk with your doctors about what option is best for you.

I was excited to have a plan to get better.

Sue, medical professional with PI

Where Ig Therapies Comes From1

Ig therapies come from plasma donated by healthy individuals. A donor's plasma is put through a rigorous series of tests, including screening for specific infectious diseases and measurement of protein levels and hematocrit to make sure they are both in an acceptable range for donation. Once it is determined safe for use, the plasma is sent to a processing plant where it is processed into numerous plasma based treatments, including Ig therapies.

Reference: 1. Blaese RM, Bonilla FA, Stiehm ER, Younger ME, eds. Patient & Family Handbook for Primary Immunodeficiency Diseases. 5th ed. Towson, MD: Immune Deficiency Foundation; 2013. 2. Immune Deficiency Foundation. Primary Immunodeficiency Diseases in America: 2007 The Third National Survey of Patients. Prepared by Abt. SRBI, Inc. May 2009.

Gammagard Liquid MyIgCoPayCard Program Terms and Conditions

This manufacturer's coupon program is not valid for prescriptions reimbursed, in whole or in part, by Medicaid, Medicare, Medigap, VA, DoD, TRICARE, or any other federal or state healthcare programs, including state pharmaceutical assistance programs, and where prohibited by the health insurance provider or by law

Shire's MyIgCoPayCard program provides a maximum total benefit of $5,000 for eligible out-of-pocket costs and expires 12 months from date of activation. Eligible costs include deductible, copayment, and co-insurance costs for eligible Shire IG (Immunoglobulin) products. Non-medication expenses, such as ancillary supplies or administration-related costs, are not eligible.

To be eligible, patients must: 1. be starting or receiving treatment with (and have current prescription for) an eligible Shire IG product with an ICD-10 for a diagnosis of Primary Immunodeficiency; and 2. have commercial insurance that covers medication costs for prescribed Shire IG product and allows for CoPay assistance; and 3. be two (2) years old or older.

Acceptance of this offer must be consistent with the terms of benefits provided by patient's health insurance provider.

Offer limited to one card per person and may not be combined with any other coupon, discount, prescription savings card, rebate, free trial, patient assistance, or other offer.

This program is only valid for residents of the United States.

Shire reserves the right to change or discontinue this program at any time without notice.

This is not health insurance.


Add to patient instructions:

If your insurance situation changes, it is your responsibility to notify MyIgSource's CoPay assistance program.

© 2017 Shire. All rights reserved.

SHIRE and the Shire Logo are registered trademarks of Shire Pharmaceutical Holdings Ireland Limited or its affiliates. Gammagard Liquid is a trademark or registered trademark of Baxalta Incorporated, a wholly owned, indirect subsidiary of Shire plc.

S30515 04/17

Please expand for Indication and Important Safety Information.


What is the most important information that I should know about GAMMAGARD LIQUID?

GAMMAGARD LIQUID can cause the following serious reactions: severe allergic reactions causing difficulty in breathing or skin rashes; decreased kidney function or kidney failure; blood clots in the heart, brain, lungs or elsewhere in the body; severe headache, drowsiness, fever, painful eye movements, or nausea and vomiting; dark colored urine, swelling, fatigue, or difficulty breathing.